Topic

Articles

NRG Therapeutics and Domainex aim to develop novel small-molecule drugs to treat neurodegenerative disorders, such as Parkinson’s disease.

NRG Therapeutics and Domainex Partner on Parkinson’s Disease Drug Development Project

Eli Lilly and Company has entered into a research and collaboration agreement with Entos Pharmaceuticals to develop new therapeutics for treating neurologic disorders.

Lilly and Entos Pharmaceuticals Partner in Research Collaboration to Develop Therapies for Multiple Neurologic Indications

SpringWorks Therapeutics and the Dana-Farber Cancer Institute will conduct further research into the therapeutic potential of combination therapy with nirogacestat and anti-BCMA agents for multiple myeloma.

SpringWorks Therapeutics and Dana-Farber Team Up to Further Evaluate Potential Multiple Myeloma Treatment

Pfizer’s proposed $2.26-billion acquisition of Trillium Therapeutics will add next-generation hematology-targeted immuno-therapeutics to its oncology pipeline.

Pfizer to Acquire Trillium Therapeutics in $2.26-Billion Deal

FDA has approved AstraZeneca’s Saphnelo, a type I interferon receptor antibody for treating systemic lupus erythematosus.

FDA Approves AstraZeneca’s Lupus mAb, Saphnelo

Byondis and Glycotope have formed an agreement to discover and develop antibodies that target specific glyco-epitopes.

Byondis and Glycotope Partner on Discovery and Development of Glyco-Epitope-Targeting Antibodies

Amgen’s Aimovig has become the first and only approved treatment in Japan for treating migraine attacks in adults by blocking the CGRP-R.

Amgen’s Aimovig Approved in Japan for Treating Migraine

FDA has granted breakthrough therapy designation to donanemab, Eli Lilly and Co.’s investigational antibody treatment for Alzheimer’s disease.

Lilly's Investigational Alzheimer's Therapeutic Gets Breakthrough Therapy Designation

Projects led by collaborating researchers from both Sanofi and Stanford Medicine will focus on autoimmune diseases and inflammatory conditions.

Sanofi Forms Three-Year Immunology Research Collaboration with Stanford Medicine

Eli Lilly and Company has partnered with leading diabetes tech firms to offer app compatibility with insulin smart pens to streamline diabetes management with automated data collection.

Therapeutic-Specific Areas